Skip to main
COLL
COLL logo

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 11%
Hold 22%
Sell 0%
Strong Sell 11%

Bulls say

Collegium Pharmaceutical Inc. showcases a strong financial outlook, bolstered by a projected top-line guidance of $735 million to $750 million for 2025, reflecting a substantial $155 million increase attributed to the promising growth potential of Jornay PM, despite initial skepticism in the ADHD market. The company demonstrates robust financial management and confidence, evidenced by a $60 million stock repurchase in 2024 and an additional $90 million authorized, highlighting management's belief in the company’s growth trajectory. Furthermore, the firm boasts an impressive near 60% EBITDA margin while maintaining a healthy cash flow exceeding $300 million annually, positioning it favorably for future investments and strategic expansion.

Bears say

Collegium Pharmaceutical Inc. faces significant challenges that contribute to a negative outlook for its stock, despite being perceived as undervalued with a 4.2x EV/EBITDA ratio based on 2025 projections. Key financial metrics indicate risks in commercialization related to potential delays and quality compliance issues that could adversely affect profitability. Additionally, the company's portfolio is under pressure from generic competition in the pain management market, which impacts its market access and reimbursement rates, further limiting its growth prospects compared to peers.

Collegium Pharmaceutical (COLL) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 11% recommend Buy, 22% suggest Holding, 0% advise Selling, and 11% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 9 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.